Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last? [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
Ocular Therapeutix, Inc. (OCUL)
Last ocular therapeutix, inc. earnings: 3/12 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ocutx.com
Company Research
Source: Yahoo! Finance
The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 5.9% gain over the past four weeks. Investors are positive on Ocular's pipeline and regulatory updates. In August, OCUL received a written response from the FDA stating that the late-stage SOL-R study is appropriate for use as the second adequate and well controlled study on Axpaxli (axitinib intravitreal implant) for the treatment of patients with wet age-related macular degeneration. The first subjects have been enrolled in the SOL-R non-inferiority study evaluating repeat dosing of Axpaxli. Enrollment in the SOL-1 superiority study evaluating a single AXPAXLI implant continues to accelerate This biotechnology company is expected to post quarterly loss of $0.23 per share in its upcoming report, which represents a year-over-year change of +54.9%. Revenues are expected to be $17.68 million, up 17.2% from the year-ago quarter. While earni
Show less
Read more
Impact Snapshot
Event Time:
OCUL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCUL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCUL alerts
High impacting Ocular Therapeutix, Inc. news events
Weekly update
A roundup of the hottest topics
OCUL
News
- Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting [Yahoo! Finance]Yahoo! Finance
- Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual MeetingGlobeNewswire
- Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR [Yahoo! Finance]Yahoo! Finance
- Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDRGlobeNewswire
OCUL
Earnings
- 11/14/24 - Beat
OCUL
Analyst Actions
- 12/3/24 - HC Wainwright
OCUL
Sec Filings
- 2/14/25 - Form 8-K
- 2/14/25 - Form SCHEDULE
- 2/13/25 - Form 4
- OCUL's page on the SEC website